Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 476 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 150 Minutes Week Clear all
Active, not recruiting Not applicable Interventional

Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa

NCT02086890
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Electro-acupuncture, Laser Acupuncture, Transcorneal Electrical Stimulation, Sham Electro-acupuncture, Sham laser acupuncture, Sham transcorneal electrical stimulation
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 4 Interventional

OnabotulinumtoxinA in the Management of Psychogenic Dystonia

NCT02618889
View directory record Official record
Conditions
Torticollis, Dystonia
Interventions
CBT
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 13, 2026, 6:37 PM EDT
Terminated Not applicable Interventional

Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo

NCT02217033
View directory record Official record
Conditions
Breast Cancer
Interventions
'R' (Electro-kinetically altered beverage), Placebo (water)
Other
Lead sponsor
South Sound Care Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Bonney Lake, Washington • Federal Way, Washington • Gig Harbor, Washington + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 13, 2026, 6:37 PM EDT
Active, not recruiting Not applicable Interventional

Telehealth Weight Loss Program for Breast Cancer Survivors

NCT04855552
View directory record Official record
Conditions
Cancer Survivors, Cancer of Breast, Body Weight, Overweight and Obesity
Interventions
Behavioral Weight-loss Program Via Telehealth, Behavioral Weight-Loss Program Via Telehealth - Weight Measures, Validated Surveys of Patient-Reported Outcomes
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

NCT03423238
View directory record Official record
Conditions
Obesity, Weight Loss, CHD - Coronary Heart Disease
Interventions
Exercise, Health Education, Exercise Compliance, Calorie-Restricted Diet, Behavioral Modification, Weight-Loss Compliance, Dietary Counseling
Other · Behavioral · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00550537
View directory record Official record
Conditions
Lung Cancer
Interventions
bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
7
States / cities
Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Not applicable Interventional Results available

Changing Lifestyles for Better Health

NCT00848757
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Intensive Lifestyle Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Madres Para la Salud (Mothers for Health)

NCT01908959
View directory record Official record
Conditions
Overweight and Obesity, Depression, Postpartum, Mother (Person)
Interventions
Madres para la Salud
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional

Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors

NCT07706556
View directory record Official record
Conditions
Breast Cancer
Interventions
Affect-based Exercise Prescription, Effort-based exercise prescription, Standard Exercise Promotion Program, Step-up Exercise Promotion Program
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 1 Interventional

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

NCT00672295
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Dasatinib, Paclitaxel, and Carboplatin
Drug
Lead sponsor
AA Secord
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Tampa, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting Phase 2 Interventional

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

NCT06941857
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, Folinic Acid, 5-Fluorouracil (5-FU), NC410, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 2 Interventional Results available

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

NCT00563784
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer
Interventions
Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Test of Five Weight Neutral Interventions to Improve Health Among Adults of Higher Body Weight

NCT07363616
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Risk Factors
Interventions
Mediterranean eating style, Physical activity, Mindful Eating, Body Appreciation, Enjoyable Exercise
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 1Phase 2 Interventional

Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients

NCT00207233
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus
Interventions
MCT oil hypocaloric liquid diet, LCT hypocaloric liquid diet, Subcutaneous abdominal adipose tissue biopsy
Behavioral · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Tirzepatide Impact Assessment Study

NCT07740291
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
Interventions
GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 2 Interventional

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

NCT00055835
View directory record Official record
Conditions
Bladder Cancer, Urethral Cancer
Interventions
carboplatin, cisplatin, gemcitabine hydrochloride, paclitaxel, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
92
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 13, 2026, 6:37 PM EDT
Not listed Phase 2 Interventional

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

NCT04672005
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Folfirinox alternating with Gemcitabine-nab-Paclitaxel
Drug
Lead sponsor
Lyudmyla Berim
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Hamilton, New Jersey • Jersey City, New Jersey • Livingston, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 13, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

EBT Fruit and Vegetable Prescription

NCT05028205
View directory record Official record
Conditions
Childhood Obesity, Obesity
Interventions
Prevention Plus
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
4 Years to 10 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Not yet recruiting Phase 4 Interventional

Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

NCT07769047
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment, Lifestyle Counseling, Semaglutide
Procedure · Other · Behavioral + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 13, 2026, 6:37 PM EDT
Terminated Phase 1Phase 2 Interventional

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions
SLC-391, pembrolizumab
Drug · Biological
Lead sponsor
SignalChem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Not applicable Interventional

Enduring Exercise Habits

NCT03634423
View directory record Official record
Conditions
Healthy
Interventions
Sweet Spot: Flexible high incentive condition, Sweet Spot: Flexible low incentive condition, Sweet Spot: Rigid high incentive condition, Sweet Spot: Rigid low incentive condition, FOTW: High incentive control condition, FOTW: Low incentive control condition, FOTW: High incentive treatment condition, FOTW: Low incentive treatment condition, Think Twice: Control condition, Think Twice: Treatment condition, WDR: Control condition, WDR: Treatment condition
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
32,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 13, 2026, 6:37 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

NCT01798485
View directory record Official record
Conditions
Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic
Interventions
Docetaxel, Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
78
States / cities
Flagstaff, Arizona • Prescott Valley, Arizona • Sedona, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 13, 2026, 6:37 PM EDT
Completed Phase 3 Interventional

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

NCT00002548
View directory record Official record
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 13, 2026, 6:37 PM EDT